Диссертация (1174348), страница 22
Текст из файла (страница 22)
J. Reprod. Immunol. – 2007. – Vol. 58, № 1. – Р. 21-30.187. Shengxu, Li Childhood Risk Factors and Pregnancy-Induced Hypertension: TheBogalusa Heart Study / Shengxu Li, Xu Xiong, Emily Harville, Tao Zhang,Dianjianyi Sun et al. // Am J Hypertens. – 2016. – Vol. 29(10). – P. 1206-11.188. Sibai, B. Preeclampsia / Sibai B., Dekker G., Kupfermic M.
// Lancet. – 2005. –Vol. 365. – P. 785–799.189. Sibai, B.M. A protocol for managing severe preeclampsia in the second trimester/ Sibai B.M., Akl S., Fairlie F., Moretti M. // Am J Obstet Gynecol. – 1990. – Vol.163. – P. 733–738.190. Sibai, B.M. Aggressive versus expectant management of severe preeclampsia at28 to 32 weeks’ gestation: a randomized controlled trial / Sibai B.M., MercerB.M., Schiff E., et al. // Am J Obstet Gynecol. – 1994.
– Vol. 171. – P. 818–22.191. Sibai, B.M. Diagnosis and management of atypical preeclampsia-eclampsia /Sibai B.M., Stella C.L. // Am J Obstet Gynecol. – 2009. – Vol 200:481.e1-481.e7.192. Sibai, B.M. Expectant management of severe preeclampsia remote from term:patient selection, treatment, and delivery indications / Sibai B.M., Barton J.R. //Am J Obstet Gynecol. – 2007. – Vol.
196. – P. 514-19.193. Sibai, B.M. Maternal and perinatal outcome of conservative management ofsevere preeclampsia in mid-trimester / Sibai B.M., Taslimi M., Abdella T.N. et all.135// American Journal of Obstetrics and Gynecology. – 1985. – Vol. 152. – P. 32-7.194. Sibai, B.M. Risk factors for preeclampsia in healthy nulliparous women: aprospective multicenter study / Sibai B.M., Gordon T., Thom E., Caritis S.N.,Klebanoff M., McNellis D., Paul R.H. // The National Institute of Child Health andHuman Development Network of Maternal-Fetal Medicine Units.
Am J ObstetGynecol. – 1995. – Vol. 172. –P. 642–648.195. Singh, A. Role of inflammatory cytokines and eNOS gene polymorphism inpathophysiology of pre-eclampsia / A. Singh [et al.] // Am J Reprod Immunol. –2010. – Vol. 63, № 3. – Р. 244-251.196. Skjaerven, R. Recurrence of pre-eclampsia across generations: exploring fetal andmaternal genetic components in a population based cohort / R. Skjaerven [et al.] //British Medical Journal.
– 2005. – Vol. 331, № 7521. – Р. 877–879.197. Sohlberg, S. Maternal body mass index, height, and risks of preeclampsia / S.Sohlberg [et al.] // Am J Hypertens. – 2012. – Vol. 25, № 1. – Р. 120-125.198. Sohlberg, S. Placental perfusion in normal pregnancy and early and latepreeclampsia: a magnetic resonance imaging study / S. Sohlberg [et al.] // Placenta.– 2014. – Vol. 35, № 3. – Р. 202-206.199. Song, L.
Association between Interleukin-10 gene polymorphisms and riskof early-onset preeclampsia / L. Song, M. Zhong // Int J Clin Exp Pathol. –2015. – Vol. 8, № 9. – Р. 11659-11664.200. Sowmya, S. Evaluation of Interleukin-10 (G-1082A) Promoter Polymorphism inPreeclampsia / S.
Sowmya [et al.] // J Reprod Infertil. – 2013. – Vol. 14, № 2. – Р.62-66.201. Stonek, F. A tumor necrosis factor-alpha promoter polymorphism and pregnancycomplications: results of a prospective cohort study in 1652 pregnant women / F.Stonek [et al.] // Reprod Sci. – 2007.
– Vol. 14, № 5. – Р. 425-429.202. Stonek, F. Absence of an association of tumor necrosis factor (TNF)-alphaG308A, inter- leukin-6 (IL-6) G174C and interleukin-10 (IL-10) G1082Apolymorphism in women with preeclampsia / F. Stonek [et al.] // J ReprodImmunol. – 2008. – Vol. 77, № 1. – Р. 85-90.136203. Stonek, F. Interleukin-10 -1082 G/A promoter polymorphism and pregnancycomplica- tions: results of a prospective cohort study in 1,616 pregnant women / F.Stonek [et al.] // Acta Obstet Gynecol Scand.
– 2008. – Vol. 87, № 4. – Р. 430-433.204. Svensson-Arvelund, J. The placenta in toxicology. Part II: systemic and localimmune adaptations in pregnancy / Svensson-Arvelund J., Ernerudh J., Buse E.,Cline J.M., Haeger J.D., Dixon D., et al. // Toxicol Pathol. – 2014. – Vol. 42(2). –P. 327–3810.205.
Swamy, M.K. Maternal and perinatal outcomes during expectant management ofsevere preeclampsia between 24 and 34 week of gestation / Swamy M.K., PatilKamal, Nageshu Shailaja. // The Journal of Obstetrics and Gynecology of India. –2012. – Vol. 62(4). – P. 413–418.206. Taylor, R.N. Longitudinal serum concentrations of placental growth factor:evidence for abnormal placental angiogenesis in pathologic pregnancies / TaylorR.N., Grimwood J., Taylor R.S., McMaster M.T., Fisher S.J., North R.A.
// Am JObstet Gynecol. – 2003. – Vol. 188. – P. 177-82.207. The FIGO textbook of pregnancy hypertansion / Magee L.A., von Dadelszen P.,Stones W. // UK: The Global Library of Women’s Medicine – 2016.208. Tidwell, S.C. Low maternal serum levels of placenta growth factor as anantecedent of clinical preeclampsia / Tidwell S.C., Ho H.N., Chiu W.H., TorryR.J., Torry D.S. // Am J Obstet Gynecol.
– 2001. – Vol. 184. – P. 1267-72.209. Tinsley, J.H. Interleukin-10 reduces inflammation, endothelial dysfunction, andblood pressure in hypertensive pregnant rats / J. H. Tinsley [et al.] // Am. J.Physiol. Regul. Integr. Comp. Physiol. – 2010. – Vol. 298, № 3. – Р. 713-719.210. Valdes, G. Vasodilator factors in the systemic and local adaptations to pregnancy/ G. Valdes [et al.] // Reprod. Biol. Endocrinol.
– 2009. – Vol. 7. – P. 79-85.211. Valensise, H. Early and late preeclampsia: Two different maternal hemodynamicstates in the latent phase of the disease / H. Valensise [et al.] // Hypertension. –2008. – Vol. 52. – Р. 873-880.212. Van der Merwe, J.L. Are early and late preeclampsia distinct subclasses of thedisease – what does the placenta reveal? / J. L. van der Merwe [et al.] // Hypertens137Pregnancy.
– 2010. – Vol. 29, № 4. – Р. 457-467.213. Wallace, A.E. Extravillous trophoblast and decidual natural killer cells: aremodelling partnership / Wallace A.E., Fraser R., Cartwright J.E. // Hum ReprodUpdate. – 2012. Vol. 18(4). – P.458–471.214. Wheeler, T. Relationship between maternal serum vascular endothelial growthfactor concentration in early pregnancy and fetal and placental growth / WheelerT., Evans P.W., Anthony F.W., Godfrey K.M., Howe D.T., Osmond C.
// HumReprod. – 1999. – Vol. 14. – P.1619-23.215. Wilczynski, J.R. Lymphocyte subset distribution and cytokine secretion in thirdtrimester decidua in normal pregnancy and preeclampsia / Wilczynski J.R.,Tchórzewski H., Banasik M., Głowacka E., Wieczorek A., Lewkowicz P., et al. //Eur J Obstet Gynecol Reprod Biol. – 2003. – Vol.
109(1). – P. 8–15.216. Williams, P.J. Altered decidual leukocyte populations in the placental bed in preeclampsia and foetal growth restriction: a comparison with late normal pregnancy /Williams P.J., Bulmer J.N., Searle R.F., Innes B.A., Robson S.C. // Reproduction.– 2009. – Vol. 138(1). – P.
177–84.217. Wright, D. Competing risks model in screening for preeclampsia by maternalcharacteristics and medical history / D. Wright [et al.] // Am J Obstet Gynecol. –2015. – Vol. 213, № 1. – Р. 62-72.218. Wu, Y. Vascular endothelial growth factor receptor 1, a therapeutic target incancer, inflammation and other disorders / Wu Y., Zhu Z. // Curr Med Chem. –2009. – Vol.16. – P. 2890-8.219. Xie, C. A meta-analysis of tumor necrosis factor-alpha, interleukin-6, andinterleukin-10 in preeclampsia / C. Xie [et al.] // Cytokine.
– 2011. – Vol. 56, № 3.– Р. 550-559.220. Yu, Ch.K.H. Endothelial nitric oxide synthase gene polymorphism (Glu298Asp)and devel- opment of pre-eclampsia: a case-control study and a meta-analysis /Ch.K.H. Yu [et al.] // Pregnancy and Childbirth. – 2006. – Vol. 6. – Р. 7-14.221. Zhang, J. Epidemiology of pregnancyinduced hypertension / Zhang J., Zeisler J.,Hatch M.C., Berkowitz G. // Epidemiol Rev. – 1997. – Vol. 19.
– P. 218–232. 179.138222. Zhang, J. Z. Risk factors of recurrent preeclampsia and its relation to maternaland offspring outcome / J. Z. Zhang, J. He // Zhejiang Da Xue Xue Bao Yi XueBan. – 2015. – Vol. 44, № 3. – Р. 258-263.223. Zhong, Y. First-trimester assessment of placenta function and the prediction ofpreeclampsia and intrauterine growth restriction / Zhong Y., Tuuli M., Odibo A.O.// Prenat Diagn. – 2010. – Vol.
30(4). – P. 293-308. 224. Zhong, Y. Serum screening in first trimester to predict pre-eclampsia, small forgestational age and preterm delivery: systematic review and meta-analysis / Y.Zhong [et al.] // BMC Pregnancy Childbirth. – 2015. – Vol. 15. – Р. 191-201.225. Zhong, Y. Serum screening in first trimester to predict preeclampsia, small forgestational age and preterm delivery: systematic review and meta-analysis / YanZhong, Fufan Zhu, Yiling Ding // Pregnancy and Childbirth. – 2015.
– Vol. 15. –P. 191.226. Zhou, L. Association of gene polymorphisms of FV, FII, MTHFR, SERPINE1,CTLA4, IL10, and TNFalpha with pre-eclampsia in Chinese women / Zhou L. [etal.] // Inflamm Res. – 2016. – Vol. 65, № 9. – Р. 717-724..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
